Lecanemab

Specification

• Cat#: THA-0111
• Product Name: Lecanemab
• Description: Lecanemab is an amyloid beta-targeting antibody used to treat Alzheimer's Disease in patients with mild cognitive impairment or mild dementia with a known amyloid beta pathology.
• Sequences: Lecanemab heavy chain: EVQLVESGGGLVQPGGSLRLSCSASGFTFSSFGMHWVRQAPGKGLEWVAYISSGSSTIYYGDTVKGRFTISRDNAKNSLFLQMSSLRAEDTAVYYCAREGGYYYGRSYYTMDYWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK Lecanemab light chain: DVVMTQSPLSLPVTPGAPASISCRSSQSIVHSNGNTYLEWYLQKPGQSPKLLIYKVSNRFSGVPDRFSGSGSGTDFTLRISRVEAEDVGIYYCFQGSHVPPTFGPGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
• Molecular Weight: 150000.0 Da (approximate)
• Introduction: Lecanemab is a recombinant humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble and insoluble forms of amyloid beta (Aβ), which are implicated in the pathophysiology of Alzheimer's disease. Lecanemab works to reduce Aβ plaques and prevent Aβ deposition in the brain with high selectivity to Aβ protofibrils. In clinical trials, it significantly reduced brain Aβ plaques compared to placebo. On January 6, 2023, lecanemab was granted accelerated approval by the FDA for the treatment of Alzheimer's Disease. It was granted full FDA approval on July 6, 2023.
• Purity: >99% by SDS-Page and HPLC analysis
• Formula: C6544H10088N1744O2032S46
• Appearance: Liquid

Pharmaceutical Information

• Pharmacodynamics: Lecanemab reduces amyloid-β (Aβ) plaques in a dose- and time-dependent manner. In clinical trials, lecanemab also reduced plasma P-tau181.
• Targets: Amyloid-beta precursor protein